First-in-man feasibility study of a novel ingestible magnetically inflated balloon capsule for treatment of obesity

Abstract

Intragastric balloons (IGBs) are an established treatment option for obesity. Major barriers to dissemination of IGBs include lack of long-term efficacy outcomes, safety concerns, cost, and tolerability. We developed a novel ingestible magnetically inflated balloon capsule (IMI-BC) in hopes of overcoming these challenges. The IMI-BC is significantly cheaper than IGBs currently available on the market. We performed proof-of-concept animal studies and a first-in-human feasibility study to demonstrate the feasibility of inflating the IMI-BC using an external magnet. Further studies are currently being conducted to evaluate the safety, tolerability, and long-term efficacy of the IMI-BC. When fully developed, we anticipate that this device will benefit obese patients.

Publikationsverlauf

Eingereicht: 19. Juni 2019

Angenommen: 30. Dezember 2019

Artikel online veröffentlicht:
17. April 2020

• References

• 1 Whitlock G, Lewington S, Sherliker P. et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373: 1083-1096
• 2 Genco A, Lorenzo M, Baglio G. et al. Does the intragastric balloon have a predictive role in subsequent LAP-BAND^® surgery? Italian multicenter study results at 5-year follow-up. Surg Obes Relat Dis 2014; 10: 474-478
• 3 Ponce J, Quebbemann BB, Patterson EJ. Prospective, randomized, multicenter study evaluating study and efficacy of intragastric dual-balloon in obesity. Surg Obes Relat Dis 2013; 9: 290-295
• 4 Do TN, Seah TET, Ho KY. et al. Development and testing of a magnetically actuated capsule endoscopy for obesity treatment. PLoS ONE 2016; 11: e0148035
• 5 Phee SJ, Wong KJ, Tan SL. et al. Balloon inflating device and a method for inflating a balloon. U.S. Patent 9375554. 28.06.2016